Peptide Field Reference

Tirzepatide

FDA-approved dual GLP-1/GIP agonist — the gold-standard weight loss peptide with proven clinical results.

Looking to buy tirzepatide in the Philippines? This page covers the molecule itself — dosing, mechanism, and side effects. For Philippines-specific Mounjaro availability, Zepbound status, pricing, and supplier verification, read the 2026 guide. Read the Tirzepatide Philippines 2026 guide →

What is Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and sold commercially as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It was FDA approved in 2022, making it the best-studied weight loss peptide with the most extensive clinical safety data.

The SURMOUNT-1 clinical trial demonstrated an average weight reduction of 22.5% (up to 26.6% in the highest dose group) over 72 weeks — results that had never been seen with any pharmaceutical or peptide before Retatrutide. It rapidly became the most prescribed weight loss medication in the United States.

In Philippines, research-grade tirzepatide is available at a fraction of the cost of branded Mounjaro. For users who want proven results with robust safety data and would prefer the next step up from semaglutide, tirzepatide is typically the first recommendation. Browse all weight loss peptide options to compare.

§ 02

How it works

GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, slow gastric emptying, improve insulin secretion, and reduce blood sugar. This is the same receptor targeted by Semaglutide (Ozempic).

GIP Agonism: GIP receptors in adipose tissue and the brain appear to work synergistically with GLP-1 to enhance the appetite-suppressing effects. GIP agonism also appears to reduce some of the GLP-1-induced nausea, giving Tirzepatide a better tolerability profile than pure GLP-1 agonists.

Together these two mechanisms produce metabolic effects significantly greater than either alone — a phenomenon called receptor co-agonism.

Tirzepatide in the Philippines

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) reached Philippine pharmacy shelves about 18 months behind semaglutide and remains less reliably stocked. Mercury Drug central branches in Makati and BGC carry it, but stockouts of 1–3 weeks are still common. St. Luke's BGC and Makati Med both prescribe it, but the wait between fills is the main friction.

The research-grade route has matured fast: 30mg vials with verified COAs are standard from the same suppliers that ship semaglutide. Pricing dropped through 2025 — a 30mg research vial now runs PHP 6,500–9,500 (USD 115–170), versus PHP 28,000–34,000 (USD 500–610) for a 12.5mg branded Mounjaro pen at Makati Med.

Most experienced Manila buyers running tirz protocols use research-grade for the dose-titration phase (12 weeks of 2.5–5mg) where the cost gap matters most, then either continue research-grade or transition to branded for long-term maintenance based on supply reliability that month.

Hospitals · prescription routes

Makati Medical CenterMakatiMounjaro/Zepbound prescriptions through endocrinology; in-house pharmacy stocks both
St. Luke's Medical Center BGCBGCWellness-medicine clinic prescribes; Zepbound stocked when available
The Medical CityPasigEndocrinology + diabetes center
Asian HospitalAlabangSouth Metro endocrinology fallback

Pharmacies · branches with confirmed stock

Mercury Drug — Glorietta / Greenbelt / Ayala AveMakatiMounjaro stocked; Zepbound less consistent
Mercury Drug — High Street CentralBGCComparable to Makati core
Watson's — GloriettaMakatiReliable secondary; ask the pharmacist directly for stock check

Real PH pricing · observed

Mounjaro 5mg pen (Rx)₱18,500–22,000$330–390Makati Med in-house pharmacy, May 2026
Mounjaro 12.5mg pen (Rx)₱28,000–34,000$500–610Makati Med, when in stock
Zepbound 5mg pen (Rx)₱20,500–24,000$365–430St. Luke's BGC
Research-grade tirzepatide 30mg vial₱6,500–9,500$115–170Local supplier with COA, May 2026
Endocrinology consult (specialist)₱1,500–2,500$27–45Makati Med / St. Luke's

Customs · Import reality

Tirzepatide research-grade vials follow the same import treatment as semaglutide. BOC tolerates personal-research quantities under 30 vials; larger shipments draw inspection. Cold-chain handling is more critical than for semaglutide because tirzepatide is more temperature-sensitive — verify your supplier ships with insulated packaging and ice packs sized for your route.

§ 03

Reported benefits

0122.5% average weight reduction in SURMOUNT-1 trial
02FDA approved with extensive Phase 3 clinical safety data
03Better GI tolerability vs Semaglutide (due to GIP co-agonism)
04Improved glycemic control for diabetic and pre-diabetic users
05Cardiovascular risk reduction (ongoing trials)
06Once-weekly dosing
07Strong appetite suppression with reduction in food cravings

§ 04

Dosing protocol

Suggested titration
Phase	Dose	Frequency	Duration
Starting	2.5mg	Once weekly	Weeks 1–4
Titration 1	5mg	Once weekly	Weeks 5–8
Titration 2	7.5mg	Once weekly	Weeks 9–12
Titration 3	10mg	Once weekly	Weeks 13–16
Maintenance	10–15mg	Once weekly	Ongoing

Always start at the lowest effective dose and titrate up gradually.

§ 05

Side effects

Common

Nausea (most common, typically mild with proper titration)
Diarrhea
Vomiting (usually during dose increases)
Constipation
Decreased appetite
Injection site reactions

Rare

·Pancreatitis (rare but serious — seek immediate medical attention)
·Gallbladder disease
·Hypoglycemia (mainly in diabetics on insulin)
·Acute kidney injury (from dehydration due to GI side effects)

§ 06

Who should not use Tirzepatide

§ 07

What to expect

Week 1–4 (2.5mg)

Mild nausea common. Appetite starts to reduce. Most users lose 1–3kg from water weight and reduced caloric intake.

Week 5–12

Nausea typically resolved. Steady weight loss begins. Food cravings significantly reduced. Energy usually stable.

Month 3–6

Consistent 0.5–1.5kg/week loss when combined with reasonable diet. Body composition clearly changing. Clothes fitting differently.

Month 6+

Weight loss slows as you approach a lower set point. Maintenance dose identified. Many users plateau around their new metabolic equilibrium.

§ 08

FAQ

Q-01

Is generic Tirzepatide the same as Mounjaro?

The active molecule is identical. The difference is that branded Mounjaro goes through strict pharmaceutical manufacturing and regulatory oversight. Research-grade Tirzepatide varies in quality by supplier, which is why COA verification is essential. See the full Mounjaro vs research-grade comparison for Philippines buyers.

Q-02

Should I choose Tirzepatide or Retatrutide?

Tirzepatide has superior clinical safety data and is FDA approved. Retatrutide shows higher weight loss (~6% more) but is still in Phase 3. For your first GLP-1 experience, Tirzepatide or Semaglutide is usually recommended.

Q-03

What if I plateau on Tirzepatide?

Plateaus are common after 3–6 months. Options include: increase dose to the next titration step, add resistance training, audit protein intake (aim for 1.6–2g/kg), or consider switching to Retatrutide for additional metabolic effect.

Q-04

Can I take Tirzepatide and BPC-157 together?

Yes, many users combine GLP-1 peptides with healing peptides like BPC-157. There are no known negative interactions. BPC-157 may even help with GI side effects from Tirzepatide.

§ 09

Where to get Tirzepatide in the Philippines

Mounjaro is intermittently available at major Filipino pharmacies and international hospitals; Zepbound is not registered with the DAV. For full Philippines pricing, hospital routes, and research-grade supplier verification, see our Tirzepatide Philippines 2026 guide. For the legal framework around peptides in the Philippines, see our legality guide. Then browse the community-verified supplier list.

Tirzepatide Philippines 2026 Guide Community Supplier List

Primary sources

Citations supporting the clinical claims on this page. Each entry links to the primary record.

[01]
SURPASS-2 Trial — tirzepatide vs semaglutide
Trial
Frias JP et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med 2021;385:503-515.
DOI: 10.1056/NEJMoa2107519
[02]
SURMOUNT-1 Trial — tirzepatide for obesity
Trial
Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med 2022;387:205-216.
DOI: 10.1056/NEJMoa2206038
[03]
SURMOUNT-4 — weight maintenance
Trial
Aronne LJ et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction." JAMA 2024;331(1):38-48.
DOI: 10.1001/jama.2023.24945
[04]
Mounjaro Prescribing Information — FDA Label
Label
Eli Lilly. Mounjaro (tirzepatide) injection prescribing information. US FDA-approved label.
Source
[05]
Dual GIP/GLP-1 receptor agonist mechanism
Mechanism
Coskun T et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Mol Metab 2018;18:3-14.
DOI: 10.1016/j.molmet.2018.09.009

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician — ideally one with peptide-specific clinical experience — before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status

Independent · Non-clinical

Affiliation

Not a clinic · Not a pharmacy

Last Updated

May 7, 2026

↗ Related peptides

Retatrutide Semaglutide Cagrilintide AOD-9604

↗ Related guides